Research discovers fibronectin’s role in BRAF-mutant thyroid cancer resistance

  • Post author:
  • Post category:uncategorized

New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, PhD, could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF gene -; a mutation also responsible for some types of melanoma, colorectal cancer, leukemia, lymphoma, and ovarian cancer.